Pesquisar
Chemomab Therapeutics Ltd
CMMBAdicionar à lista de desejos
2.270USD
+0.550+31.98%
Fechamento 07/02, 13:00（ET）Cotações atrasadas em 15 min
65.38MValor de mercado
13.03P/L TTM
Mais detalhes de Chemomab Therapeutics Ltd Empresa
Chemomab Therapeutics Ltd (formerly known as Anchiano Therapeutics Ltd) is a Israel-based clinical-stage biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of fibrotic and inflammatory diseases with high unmet medical need among others. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
Informações de Chemomab Therapeutics Ltd
Código da empresaCMMB
Nome da EmpresaChemomab Therapeutics Ltd
Data de listagemAug 14, 2012
CEOMor (Adi)
Número de funcionários16
Tipo de títulosDepository Receipt
Fim do ano fiscalAug 14
EndereçoKiryat Atidim, Building 7
CidadeTEL AVIV-YAFO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísIsrael
Código postal6158002
Telefone972773310156
Sitehttps://www.chemomab.com/
Código da empresaCMMB
Data de listagemAug 14, 2012
CEOMor (Adi)
Executivos da empresa Chemomab Therapeutics Ltd
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Sigal Fattal, CPA
Ms. Sigal Fattal, CPA
Chief Financial Officer
Chief Financial Officer
14.48K
+95.59%
Dr. Nissim Darvish, M.D. Ph.D.
Dr. Nissim Darvish, M.D. Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
300.00
--
Mr. Neil Cohen
Mr. Neil Cohen
Independent Director
Independent Director
--
--
Dr. Adi Mor, Ph.D.
Dr. Adi Mor, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
Ms. Irina Koffler
Ms. Irina Koffler
Investor Relations
Investor Relations
--
--
Dr. David M. Weiner, M.D.
Dr. David M. Weiner, M.D.
Interim Chief Medical Officer
Interim Chief Medical Officer
--
--
Mr. Jack Lawler
Mr. Jack Lawler
Chief Development Officer
Chief Development Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Sigal Fattal, CPA
Ms. Sigal Fattal, CPA
Chief Financial Officer
Chief Financial Officer
14.48K
+95.59%
Dr. Nissim Darvish, M.D. Ph.D.
Dr. Nissim Darvish, M.D. Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
300.00
--
Mr. Neil Cohen
Mr. Neil Cohen
Independent Director
Independent Director
--
--
Dr. Adi Mor, Ph.D.
Dr. Adi Mor, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de Chemomab Therapeutics Ltd?
Os cinco principais acionistas de Chemomab Therapeutics Ltd são: Ms. Sigal Fattal, CPA
Quantas instituições possuem ações da Chemomab Therapeutics Ltd (CMMB)?
Em 2026Q1, 33 instituições possuíam ações da Chemomab Therapeutics Ltd, com valor de mercado aproximado de 402.96K, representando 5.60% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -450971.00.